Navigation Links
Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia,Long-Term Safety Data at AAN Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 1, 2007 - Avanir Pharmaceuticals (NASDAQ:AVNR) today announced that data on the long-term safety of the investigational drug Zenvia(TM) (dextromethorphan / quinidine) and the prevalence of Involuntary Emotional Expression Disorder (IEED) were presented today during a poster session at the American Academy of Neurology (AAN) 59th Annual Meeting in Boston. The information was presented in the following posters: -0-
    1.  Poster P01.090: Involuntary Emotional Expression Disorder

        (IEED) Prevalence and Treatment


    2.  Poster P01.015: Long-Term Safety of AVP-923

        (Dextromethorphan/Quinidine) in the Treatment of Involuntary

        Emotional Expression Disorder (IEED)


    3.  Poster P01.016: Competitive Binding of Dextromethorphan to

        Selective Brain Receptor Sites

Walter Bradley, DM, FRCP, Professor and Chairman Emeritus, Department of Neurology at the University of Miami School of Medicine presented poster P01.090 "Involuntary Emotional Expression Disorder (IEED) Prevalence and Treatment." In this study a representative sample of 2318 patients in the U.S. with neurologic diseases or injuries known to cause IEED, or their caregivers, were surveyed to determine the prevalence of IEED symptoms. The results indicate that at least 1.8 million neurologic patients in the U.S. suffer from frequent and intense episodes of uncontrollable crying or laughing. In addition, the data indicate that up to 7 million neurologic patients suffer some degree of impairment caused by uncontrollable laughing or crying. Fifty nine percent of patients with IEED symptoms had discussed their symptoms with their physician and less than half received any diagnosis or treatment. The authors concluded that the prevalence of IEED in the U.S. appears to be greater than previously estimated in the medical literature and that education is needed to improve diagnosis and treatment. These data were deemed especially n
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/1/2014)... --  Cypher Genomics, Inc., the genome informatics company, ... as chief technology officer. Ravenel has more than ... a proven track record of designing and architecting solutions ... been recognized as a top designer and architect of ... for delivering innovative products that operate at scale and ...
(Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
(Date:9/30/2014)... This report analyzes the worldwide markets for Enteral ... Enteral Feeding Pumps, Nasogastric Tubes, and Others. The ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. The report ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19
(Date:10/1/2014)... PA, October 1, 2014 Patients with increased ... have a greatly increased risk of depression. For ... for chronic hepatitis C virus infection causes depression ... fatty acids, more commonly known as fish oil, ... lowering the risk of heart disease and reducing ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... 2014 First Warning Systems, a pioneer ... changes throughout the body, announced the company is changing ... the company’s breadth of upcoming product releases. The initial ... technology. , “Our initial focus will be an ‘Internet ... abnormal circadian cellular changes over time,” said Rob Royea, ...
(Date:10/1/2014)... Join the more than 80 golfers who already ... ever charity golf tournament to benefit Project HEAL, a not-for-profit ... cannot afford treatment. The tournament will be held Monday, Oct. ... , The day-long event starts with 10:30 a.m. check-in and ... will begin at 5 p.m. and will include an auction ...
(Date:10/1/2014)... 01, 2014 Innovations announces the upcoming ... broadcast on Monday, October 20, 2014 at 7:30 a.m. ... will go behind the scenes to learn about Break ... will explore the practical help and information Break the ... the warning signs of abuse, how to navigate the ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... Resources Allows Pharmaceutical Brand Managers to Build Patient-Flow ... 11 Decision Resources, one of the world,s ... and healthcare issues, finds that use of Novartis, ... Merck,s Cozaar is influenced by physician perception that ...
... revolutionary new line of health and beauty-nutritional supplements, will ... Avenue in New York City. Functionalab, designed to ... a globally recognized developer of science-based and professionally endorsed ... effectiveness. , , Functionalab represents ...
... May 11 Harris announced today that it is ... to prevent the spread of H1N1 and other viruses. ... the hand sanitizing gel at more than 400 new ... Airport."As Chicago,s hometown bank, we applaud our Mayor, the ...
... FARMINGDALE, N.Y., May 11 Misonix, Inc. (Nasdaq: ... technology, which in Europe is used for the ablation of ... financial results for the three and nine months ended March ... Executive Officer, and Richard Zaremba, Senior VP and Chief Financial ...
... registration for one of 2009,s largest and most important scientific ... of the American Chemical Society (ACS) will be held Aug. ... others are expected to attend the meeting, held in the ... than 8,400 reports on new discoveries about chemistry and a ...
... access to stroke specialists, especially in rural or other ... known as a "mini" or "warning" stroke, should be ... according to two separate scientific statements and a policy ... American Heart Association . , Telemedicine Statement Highlights: ...
Cached Medicine News:Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 2Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 3Health News:Functionalab Launches Exclusively at Henri Bendel Monday, May 11th, 2009 2Health News:Harris Joins City of Chicago in Support of Maintaining Good Health Habits 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 3Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 4Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 5Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 6Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 7Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 8Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 9Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 10Health News:Videoconferencing can increase patient access to stroke specialists 2Health News:Videoconferencing can increase patient access to stroke specialists 3
50L...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
250L...
Medicine Products: